|
| | HR0124 | | LRB104 10582 LAW 20658 r |
|
|
| 1 | | HOUSE RESOLUTION |
| 2 | | WHEREAS, Serious mental illnesses like bipolar disorder, |
| 3 | | major depressive disorder, and schizophrenia often require |
| 4 | | treatment with antipsychotic medications for effective |
| 5 | | management, and antipsychotic prescribing rates continue to |
| 6 | | rise; and |
| 7 | | WHEREAS, While prolonged antipsychotic use may be |
| 8 | | essential for the treatment of certain conditions, it is |
| 9 | | associated with tardive dyskinesia (TD), a condition marked by |
| 10 | | uncontrollable, abnormal, and repetitive movements of the |
| 11 | | face, torso, limbs, or extremities; and |
| 12 | | WHEREAS, People at higher risk of TD include those older |
| 13 | | than 55 years, people who are Black, women, individuals with |
| 14 | | mood or substance use disorders, intellectual disabilities, or |
| 15 | | central nervous system injuries, and those with high |
| 16 | | cumulative antipsychotic exposure; and |
| 17 | | WHEREAS, Approximately 60% of the estimated 800,000 U.S. |
| 18 | | adults living with TD remain undiagnosed, and even mild TD |
| 19 | | symptoms can be stigmatizing and impair physical, social, and |
| 20 | | emotional well-being, underscoring the urgency of early |
| 21 | | screening, detection, and intervention; and |
|
| | HR0124 | - 2 - | LRB104 10582 LAW 20658 r |
|
|
| 1 | | WHEREAS, The American Psychiatric Association recommends |
| 2 | | routine TD screening in their clinical guidelines for |
| 3 | | antipsychotic treatment, and individuals treated with |
| 4 | | antipsychotics or experiencing abnormal movements should |
| 5 | | consult their health care providers to assess TD risk, receive |
| 6 | | TD screenings, and determine appropriate treatment together; |
| 7 | | and |
| 8 | | WHEREAS, FDA-approved treatments for TD can provide |
| 9 | | options for symptom management and improved quality of life |
| 10 | | for many individuals living with TD; and |
| 11 | | WHEREAS, The General Assembly can encourage TD screening |
| 12 | | education and awareness for health care providers, patients, |
| 13 | | and care partners to help ensure patients prescribed |
| 14 | | antipsychotics receive care and support that aligns with |
| 15 | | clinical best practices, including regular TD screenings; |
| 16 | | therefore, be it |
| 17 | | RESOLVED, BY THE HOUSE OF REPRESENTATIVES OF THE ONE |
| 18 | | HUNDRED FOURTH GENERAL ASSEMBLY OF THE STATE OF ILLINOIS, that |
| 19 | | we declare May 4 through May 10, 2025 as Tardive Dyskinesia |
| 20 | | Awareness Week (TDAW) in the State of Illinois; and be it |
| 21 | | further |
| 22 | | RESOLVED, That we support TDAW in recognition of the |
|
| | HR0124 | - 3 - | LRB104 10582 LAW 20658 r |
|
|
| 1 | | importance of early detection and intervention to improve |
| 2 | | outcomes for people living with mental health conditions and |
| 3 | | prescribed antipsychotics, and we support efforts to raise |
| 4 | | awareness about the causes and symptoms of tardive dyskinesia |
| 5 | | (TD) and the importance of routine TD screening. |